Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Pharmanovia A/S Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Bankruptcy risk for industry   1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1% 1.1%   Bankruptcy risk   4.8% 39.0% 29.1% 37.3% 2.0% 2.4% 6.5% 6.3%   Credit score (0-100)   46 1 1 0 68 62 36 37   Credit rating   BBB C C C A BBB BBB BBB   Credit limit (kDKK)   -0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   10,614 3,730 15,224 3,431 5,884 4,684 0.0 0.0   EBITDA   -26.5 558 942 4,944 3,463 3,077 0.0 0.0   EBIT   -828 -1,573 -241 -2,707 3,346 2,925 0.0 0.0   Pre-tax profit (PTP)   -5,891.1 -13,715.3 -2,028.1 -21,600.4 3,283.2 2,682.8 0.0 0.0   Net earnings   -5,891.1 -1,836.0 -272.0 -2,904.0 3,508.2 2,246.6 0.0 0.0   Pre-tax profit without non-rec. items   -5,891 -3,535 -470 -4,171 3,283 2,683 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Tangible assets total   1,165 883 566 171 54.2 49.6 0.0 0.0   Shareholders equity total   -19,930 2,295 2,031 -872 2,637 4,883 4,749 4,749   Interest-bearing liabilities   37,887 6,804 5,597 62,954 14,100 34,398 0.0 0.0   Balance sheet total (assets)   24,728 3,905 3,752 10,231 18,359 47,728 4,749 4,749   Net Debt   36,229 3,210 5,175 48,198 12,883 32,377 -4,564 -4,564     See the entire balance sheet 1000.0 Volume  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   10,614 3,730 15,224 3,431 5,884 4,684 0.0 0.0   Gross profit growth   285.4% -64.9% 308.1% -77.5% 71.5% -20.4% -100.0% 0.0%   Employees   12 0 0 0 15 12 0 0   Employee growth %   50.0% -100.0% 0.0% 0.0% 0.0% -20.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   24,728 3,905 3,752 10,231 18,359 47,728 4,749 4,749   Balance sheet change%   3.5% -84.2% -3.9% 172.7% 79.4% 160.0% -90.0% 0.0%   Added value   -26.5 558.0 941.7 4,944.0 10,997.2 3,077.3 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   2,295 -2,343 2,479 -12,767 -4,404 -300 -388 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -3.0 -4.0 -5.0 -5.0 1.0 2.0 0.0 0.0   1000.0 Profitability  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   -7.8% -42.2% -1.6% -78.9% 56.9% 62.5% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -2.0% -6.5% -6.3% -36.4% 23.5% 12.2% 0.0% 0.0%   ROI %   -2.4% -8.6% 10.1% 45.2% 84.4% 14.4% 0.0% 0.0%   ROE %   -24.2% -13.6% -12.6% -7.4% 8.9% 59.7% 0.0% 0.0%   1000.0 Solidity  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Equity ratio %   -44.6% 7.9% 7.3% -1.0% 14.4% 10.2% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -136,671.0% 575.2% 549.6% 974.9% 372.0% 1,052.2% 0.0% 0.0%   Gearing %   -190.1% 296.5% 275.6% -7,219.4% 534.8% 704.4% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   14.4% 8.8% 3.7% 4.3% 0.5% 5.6% 0.0% 0.0%   1000.0 Liquidity  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Quick Ratio   1.3 1.6 1.0 2.3 1.3 0.9 0.0 0.0   Current Ratio   1.9 2.3 1.9 3.2 1.7 1.1 0.0 0.0   Cash and cash equivalent   1,658.1 3,594.7 421.6 14,755.6 1,217.3 2,020.9 0.0 0.0   1000.0 Capital use efficiency  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   8,354.4 13,022.2 8,236.2 49,208.2 7,062.5 4,309.9 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2019/3 2019 2020/3 2020 2021/3 2021 2022/3 2022 2023/3 2023 2024/3 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -2 0 0 0 733 256 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -2 0 0 0 231 256 0 0   EBIT / employee   -69 0 0 0 223 244 0 0   Net earnings / employee   -491 0 0 0 234 187 0 0